[Acetylsalicylic acid in the treatment of ischemic cerebrovascular disorders]. / L'acido acetil-salicilico nella terapia delle vasculopatie cerebrali ischemiche.

An examination of 80 patients with ischaemic cerebrovascular disease, subdivided into 5 groups according to platelet antiaggregant treatment, demonstrated the insufficient effectiveness of acetylsalicylic acid in preventing recurrences. The drug failure can most probably be attributed to its particular action mechanism or to dosage.

[Ditazol in the therapy of ischemic cerebrovascular diseases. Clinical results and laboratory experiments (22-to-34-month clinical follow-up)]. / Il ditazolo nella terapia delle vasculopatie cerebrali ischemiche. Risultati clinici ed esperienze di laboratorio (follow-up clinico 22-34 mesi).

A sample of 29 patients suffering from ischaemic cerebrovascular disorders was examined. Of these, 15 were treated with Ditazol (1200 mg/day in three administrations) and 14 with ASA (1 g a day in 2 administration). These patients were evaluated using serial Born and Cross tests to check ADP, Adrenaline and Collagen-induced platelet aggregation. The clinical follow-up lasted 22-34 months. As part of the laboratory evaluation, this sample was also compared with a group of 34 healthy volunteers. Ditazol was found to be an inhibitor of ADP, Adrenaline and Collagen-induced platelet aggregation: this effect constitutes clinical protection against recurrence of the complaint. Recurrence was 13.3% with Ditazol treated patients and 35.7% with ASA.

[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)]. / La malattia cerebrovascolare ischemica: il suo trattamento con differenti farmaci antiaggreganti piastrinici. Follow-up clinico di 80 pazienti (22-34 mesi).

Personal experience in the treatment of Ischaemic Cerebrovascular Disease with platelet suppressant drugs is reported. 80 patients were treated with 5 different protocols: 1) group "A": dipyridamol (14 patients); 2) group "B": acetylsalicylic acid (ASA) (14 patients); 3) group "C": dipyridamol and ASA (22 patients); 4) group "D": ditazol (15 patients); 5) group "E": isoxsuprine resinate (15 patients) and followed-up for 22-34 months. The evolution of the disease is discussed and recurrences evaluated on the basis of initial clinical features and particular treatment given.

[Resinated isoxsuprine in the therapy of cerebral ischemic vascular diseases]. / L'isossisuprina resinato nella terapia delle vasculopatie cerebrali ischemiche.

An examination of 80 patients with ischaemic cerebrovascular disease, subdivided into 5 groups according to platelet antiaggregant treatment, demonstrated the effectiveness of resinated Isoxysuprine in preventing recurrences. The drug's success can most probably be attributed to its particular action mechanism.